The affordable growth strategy aims to identify companies that are expanding their earnings and revenue at an above-average pace, but without the eye-watering valuations that often accompany high-growth stories. It’s a balancing act: investors want the upside of a growth stock, but they also want a price that leaves room for a reasonable return. This screen filters for stocks that demonstrate strong fundamental health and profitability, ensuring the growth is backed by a solid operational foundation rather than just market hype. One stock that currently fits this profile is Vericel Corp (NASDAQ:VCEL), a specialty biotechnology company focused on cellular therapies for cartilage repair and severe burns.
Growth: The Core of the Thesis
At the heart of the affordable growth screen is the requirement for strong expansion, and Vericel delivers well on this front. The fundamental report assigns a Growth rating of 8 out of 10, a figure driven by both historical performance and forward-looking estimates. Past earnings per share (EPS) growth has been particularly impressive, surging by 1,300% in the last year alone, with a five-year average annual EPS growth rate of 44.04%. Revenue growth is also solid, with a 22.45% increase over the last year and a consistent 17.34% average annual rate over the past five years.
Crucially for the strategy, this growth trajectory is expected to continue. Analysts project EPS will expand at an average of 49.37% per year going forward, while revenue is forecast to grow by 19.38% annually. This strong and stable outlook is a key reason Vericel passed the screen—it’s not a brief success story, but a company with a durable growth runway in its niche cell therapy markets.
Valuation: Paying a Fair Price for Future Earnings
A high price tag can quickly undermine a growth investment. The screen balances the growth narrative with a Valuation rating of 6 out of 10, which is considered reasonable for this strategy. On the surface, Vericel’s trailing Price/Earnings (P/E) ratio of 111.05 looks excessive, especially against the S&P 500 average of roughly 26.5.
However, the context matters. Within its own Biotechnology industry, Vericel actually looks attractively priced. Based on the trailing P/E, it is cheaper than 90.22% of its peers. More importantly, when looking at forward earnings and cash flow metrics, the value becomes clearer. The Price/Forward Earnings ratio of 52.18 is high in absolute terms, but the company is still cheaper than 87.48% of its industry competitors on that basis. Even more notable is the valuation based on cash flow: Vericel is cheaper than 91.19% of its industry peers on a Price/Free Cash Flow basis, and cheaper than 89.43% on an Enterprise Value to EBITDA basis. This suggests that while the earnings multiple is elevated, the market may be pricing in the future growth or undervaluing the company’s cash generation relative to its peers.
Profitability and Health: The Foundation for Sustainable Growth
The affordable growth screen isn’t just about top-line expansion; it requires a quality business underneath. Vericel’s Profitability rating of 8 out of 10 confirms it has the operational efficiency to support its growth. The company reports a Gross Margin of 74.84%, an Operating Margin of 5.40%, and a Net Profit Margin of 7.35%—all of which have been improving in recent years and rank among the top decile of the industry. Its Return on Equity (6.02%), Return on Assets (4.42%), and Return on Invested Capital (2.84%) also significantly outperform the vast majority of its biotech peers.
Financial health is another critical pillar, and Vericel earns a Health rating of 7 out of 10. While some basic checks note a slight increase in shares outstanding and a debt-to-assets ratio that has crept up, the company’s solvency is very solid. It has a top-tier Altman-Z score of 11.41, indicating minimal bankruptcy risk. The balance sheet is nearly debt-free, with a Debt/Equity ratio of 0.00 and a Debt to Free Cash Flow ratio of just 0.01, meaning it could theoretically pay off all its debt in a matter of days using free cash flow. Strong liquidity ratios (Current Ratio of 5.18, Quick Ratio of 4.79) further reinforce the company’s financial stability.
Tying It All Together
Vericel Corp ticks all the boxes of an affordable growth candidate. It offers the high-growth potential typical of a biotechnology innovator—evidenced by triple-digit EPS expansion and double-digit revenue gains—but trades at a valuation that is reasonable relative to its industry peers, not the broader market. Its underlying business is highly profitable and financially healthy, reducing the risk that is often associated with early-stage growth stories. For investors seeking a balance between growth potential and a sensible entry point, these combined characteristics make Vericel a strong example of the strategy in action.
You can review the full detail on all five fundamental rating components in the complete fundamental analysis report for VCEL.
If you'd like to explore other stocks that pass this same Affordable Growth screen, you can run the scan yourself to see a current list of candidates. More results can be found via this pre-configured stock screener link.
Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice. You should conduct your own research or consult with a financial advisor before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
Vericel Corp (NASDAQ:VCEL): An Affordable Growth Stock at a Reasonable Valuation
The affordable growth strategy aims to identify companies that are expanding their earnings and revenue at an above-average pace, but without the eye-watering valuations that often accompany high-growth stories. It’s a balancing act: investors want the upside of a growth stock, but they also want a price that leaves room for a reasonable return. This screen filters for stocks that demonstrate strong fundamental health and profitability, ensuring the growth is backed by a solid operational foundation rather than just market hype. One stock that currently fits this profile is Vericel Corp (NASDAQ:VCEL), a specialty biotechnology company focused on cellular therapies for cartilage repair and severe burns.
Growth: The Core of the Thesis
At the heart of the affordable growth screen is the requirement for strong expansion, and Vericel delivers well on this front. The fundamental report assigns a Growth rating of 8 out of 10, a figure driven by both historical performance and forward-looking estimates. Past earnings per share (EPS) growth has been particularly impressive, surging by 1,300% in the last year alone, with a five-year average annual EPS growth rate of 44.04%. Revenue growth is also solid, with a 22.45% increase over the last year and a consistent 17.34% average annual rate over the past five years.
Crucially for the strategy, this growth trajectory is expected to continue. Analysts project EPS will expand at an average of 49.37% per year going forward, while revenue is forecast to grow by 19.38% annually. This strong and stable outlook is a key reason Vericel passed the screen—it’s not a brief success story, but a company with a durable growth runway in its niche cell therapy markets.
Valuation: Paying a Fair Price for Future Earnings
A high price tag can quickly undermine a growth investment. The screen balances the growth narrative with a Valuation rating of 6 out of 10, which is considered reasonable for this strategy. On the surface, Vericel’s trailing Price/Earnings (P/E) ratio of 111.05 looks excessive, especially against the S&P 500 average of roughly 26.5.
However, the context matters. Within its own Biotechnology industry, Vericel actually looks attractively priced. Based on the trailing P/E, it is cheaper than 90.22% of its peers. More importantly, when looking at forward earnings and cash flow metrics, the value becomes clearer. The Price/Forward Earnings ratio of 52.18 is high in absolute terms, but the company is still cheaper than 87.48% of its industry competitors on that basis. Even more notable is the valuation based on cash flow: Vericel is cheaper than 91.19% of its industry peers on a Price/Free Cash Flow basis, and cheaper than 89.43% on an Enterprise Value to EBITDA basis. This suggests that while the earnings multiple is elevated, the market may be pricing in the future growth or undervaluing the company’s cash generation relative to its peers.
Profitability and Health: The Foundation for Sustainable Growth
The affordable growth screen isn’t just about top-line expansion; it requires a quality business underneath. Vericel’s Profitability rating of 8 out of 10 confirms it has the operational efficiency to support its growth. The company reports a Gross Margin of 74.84%, an Operating Margin of 5.40%, and a Net Profit Margin of 7.35%—all of which have been improving in recent years and rank among the top decile of the industry. Its Return on Equity (6.02%), Return on Assets (4.42%), and Return on Invested Capital (2.84%) also significantly outperform the vast majority of its biotech peers.
Financial health is another critical pillar, and Vericel earns a Health rating of 7 out of 10. While some basic checks note a slight increase in shares outstanding and a debt-to-assets ratio that has crept up, the company’s solvency is very solid. It has a top-tier Altman-Z score of 11.41, indicating minimal bankruptcy risk. The balance sheet is nearly debt-free, with a Debt/Equity ratio of 0.00 and a Debt to Free Cash Flow ratio of just 0.01, meaning it could theoretically pay off all its debt in a matter of days using free cash flow. Strong liquidity ratios (Current Ratio of 5.18, Quick Ratio of 4.79) further reinforce the company’s financial stability.
Tying It All Together
Vericel Corp ticks all the boxes of an affordable growth candidate. It offers the high-growth potential typical of a biotechnology innovator—evidenced by triple-digit EPS expansion and double-digit revenue gains—but trades at a valuation that is reasonable relative to its industry peers, not the broader market. Its underlying business is highly profitable and financially healthy, reducing the risk that is often associated with early-stage growth stories. For investors seeking a balance between growth potential and a sensible entry point, these combined characteristics make Vericel a strong example of the strategy in action.
You can review the full detail on all five fundamental rating components in the complete fundamental analysis report for VCEL.
If you'd like to explore other stocks that pass this same Affordable Growth screen, you can run the scan yourself to see a current list of candidates. More results can be found via this pre-configured stock screener link.
Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice. You should conduct your own research or consult with a financial advisor before making any investment decisions.
Read full article here »